

REMARKS

Because the After-final Amendment filed on July 10, 2008 was not entered according to the Advisory Action dated July 21, 2008, current amendments are based on the claims presented in the Amendment filed on February 1, 2008.

Claim Cancellation

Claims 1-77, 93 and 119-124 were canceled previously. With the cancellation of claims 126-130, 142, 163, and 165-166 by the current Amendment, claims 78-92, 94-118, 125, 131-141, 143-162, and 164 are pending.

Claim Amendments

Claim 125 is amended by excluding the unsubstituted phenyl group from Ar as suggested by the Examiner in the Advisory Action. Allowance of claim 125 is thus requested.

Claim 95 depends on claim 125. Formula 5 which is an unsubstituted phenyl is deleted from claim 95 to be consistent with the current amendment to claim 125.

Since claim 125 as amended should be allowable based on the Advisory Action, claims 78-118 and 164 which depend on claim 125 should also be allowable. Allowance of claims 78-118 and 164 is requested.

According to the Office Action of April 29, 2008 and the Advisory Action, claims 82-92, 96-106, 108-113, 115-118, 131-141 and 143-161 were objected to, but would be allowed if made independent of the rejected base claims. As a result, claims 131-141, 143-154, and 156-161 are currently amended by being made independent. Claims 82-92, 96-106, 108-113 and 115-118 are not currently amended, but claims 82-92, 96-106, 108-113 and 115-118 should be allowable by being dependent on the currently amended claim 125 as discussed above. Allowance of claims 82-92, 96-106, 108-113, 115-118, 131-141, 143-154 and 156-161 is requested.

The Office Action of April 29, 2008 holds that claim 155 would be allowed if made independent of the rejected base claim. Claim 155 was dependent on claim 94. However, upon further review, it is apparent that claim 155 should not depend on claim 94 because claim 155 further limits Formula 4, wherein Formula 4 is a Ar-N< type compound. In contrast, claim 94 recites Ar-O-X¹. Claim 155 is now made independent of claim 94. Allowance of claim 155 is requested.

Based on the current amendments, applicants request that claims 78-92, 94-118, 125, 131-141, 143-162, and 164 be allowed.

Rejections under 35 U.S.C. 103

Claims 78-81, 94, 95, 107, 114, 125-130, 142, and 162-166 were rejected under 35 U.S.C. 103(a) as allegedly being obvious over Yu (US Statutory Invention Registration H766).

Applicants thank the Examiner for indicating that claims 78-81, 94-95, 107, 114, 125-130, 142, and 162-166 would be allowed if the use of phenyl as Ar is excluded in the claims in the telephone conversation with Applicants on June 14, 2008 and in the Advisory Action dated July 21, 2008. Claims 126-130, 142, 163, and 165-166 have been cancelled, rendering the rejections of these claims moot. Claim 125 has been amended to exclude the unsubstituted phenyl as Ar. Accordingly, formula 5 in claim 95 has been deleted. Thus, claims 78-81, 94, 95, 107, 114, 125, 162, and 164 are now in condition for allowance. Applicants respectfully request the withdrawal of the rejections of these claims.

Claim Objections

Claims 82-92, 96-106, 108-113, 115-118, 131-141, and 143-161 were objected to as being dependent on a rejected base claim and would be allowed if made independent of the rejected base claim.

Claims 82-92, 96-106, 108-113, 115-118, and 155 depend on claim 125 (either directly or indirectly through the dependency on claim 94). Because claim 125 has been amended to exclude the use of a phenyl group (C₆H₅) as Ar and is believed to be in condition for allowance, Applicants respectfully request the withdrawal of the objections to claims 82-92, 96-106, 108-113, 115-118, and 155.

Claims 131-141 have been amended into independent claims by incorporating the limitations in the previously presented base claim 126. Claims 143-154 and 156-161 have amended into independent claims by incorporating the limitations in the previously presented base claims 126 and 142. Because the Office Action indicated that these claims would be allowed if made independent of the rejected base claim, Applicants respectfully request the withdrawal of the objections to claims 131-141, 143-154 and 156-161.

CONCLUSION

For at least the above reasons, applicants respectfully submit that the instant application is in condition for allowance, and request a notice from the USPTO to that effect. The Examiner is encouraged to contact applicants' representative at 202-220-4223 to resolve any outstanding issues.


In the event that the filing of this paper is deemed not timely, applicants petition for an appropriate extension of time. The Office is authorized to charge any fees (except for an issue fee), including fees for extensions of time, or credit any overpayment, to Deposit Account No. 11-0600 referencing Docket No. 11197/5.

Respectfully submitted,

KENYON & KENYON LLP

Date: August 28, 2008

1500 K Street, NW, Suite 700
Washington, D.C. 20005
202-220-4200 (tel)
202-220-4201 (fax)



King L. Wong
Reg. No. 37,500